Sugi Predict

Sugi Predict / Compounds / SCHEMBL2805013

SCHEMBL2805013

SCHEMBL2805013

BrCc1cccc2nsnc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.52
▸ MAPT P10636 4/20 0.52
▸ HSD17B10 Q99714 3/20 0.52
▸ HIF1A Q16665 1/20 0.52
▸ TXNRD1 Q16881 1/20 0.44
▸ TXNRD3 Q86VQ6 1/20 0.44
▸ TXNRD2 Q9NNW7 1/20 0.44
▸ ALDH1A1 P00352 7/20 0.43
▸ HPGD P15428 3/20 0.43
▸ TSHR P16473 2/20 0.43
▸ CASP1 P29466 2/20 0.42
▸ KMT2A Q03164 6/20 0.42
▸ MEN1 O00255 5/20 0.42
▸ POLB P06746 1/20 0.41
▸ PKM P14618 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ DUSP3 P51452 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4678156 0.84 KDM4E (0.52) KDM4EMAPTHSD17B10HIF1ATXNRD1
SCHEMBL25399698 0.80 MAPT (0.57) KDM4EMAPTHSD17B10HIF1ATXNRD1
SCHEMBL7718402 0.80 KDM4E (0.52) KDM4EMAPTHSD17B10HIF1ATXNRD1
SCHEMBL762893 0.80 KMT2A (0.56) KDM4EMAPTHSD17B10HIF1ATXNRD1
SCHEMBL13197096 0.79 KDM4E (0.47) KDM4EMAPTHSD17B10HIF1ATXNRD1
SCHEMBL14944881 0.78 KDM4E (0.55) KDM4EMAPTHSD17B10HIF1ATXNRD1
Hydrochloric Acid SCHEMBL25401492 0.78 MAPT (0.55) KDM4EMAPTHSD17B10HIF1ATXNRD1
SCHEMBL19328396 0.78 MAPT (0.32) KDM4EMAPTHSD17B10HIF1AKMT2A
SCHEMBL12844407 0.77 MAPT (0.48) KDM4EMAPTHSD17B10HIF1ATXNRD1
SCHEMBL12775851 0.76 KDM4E (0.47) KDM4EMAPTHSD17B10HIF1ATXNRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4493546-B1 IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2026-05-06 — — EP disclosed
EP-4493546-A1 IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2025-01-22 — — EP disclosed
CN-119278197-A Imidazole derivatives as potassium channel inhibitors 阿塞西翁制药公司 2025-01-07 — — CN disclosed
US-12030856-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2024-07-09 — — US disclosed
US-11945811-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2024-04-02 — — US disclosed
CN-117561247-A Novel potassium channel inhibitors 阿塞西翁制药公司 2024-02-13 — — CN disclosed
EP-4313973-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Acesion Pharma ApS (DK) 2024-02-07 — — EP disclosed
US-20230406845-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2023-12-21 — — US disclosed
US-20230399301-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2023-12-14 — — US disclosed
US-20230399301-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2023-12-14 — — US disclosed
WO-2007017414-A1 SUBSTITUTED MALONONITRILE COMPOUNDS FOR COMBATING ANIMAL PESTS BASF SE (DE) 2007-02-15 — — WO disclosed
EP-1735302-A1 4-AMINO-PIPERIDINE DERIVATIVES AS MONOAMINE UPTAKE INHIBITORS ELI LILLY AND COMPANY (US) 2006-12-27 — — EP disclosed
US-7138401-B2 2-aminopurine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION (US) 2006-11-21 — — US disclosed
US-20060142214-A1 3,6-bicyclolides ENANTA PHARMACEUTICALS, INC. 2006-06-29 — — US disclosed
EP-1670802-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS Conforma Therapeutic Corporation (US) 2006-06-21 — — EP disclosed
WO-2006063039-A2 3, 6-BICYCLOLIDES ENANTA PHARMACEUTICALS, INC. (US) 2006-06-15 — — WO disclosed
WO-2005092885-A1 4-AMINO-PIPERIDINE DERIVATIVES AS MONOAMINE UPTAKE INHIBITORS ELI LILLY AND COMPANY (US) 2005-10-06 — — WO disclosed
US-20050113340-A1 2-Aminopurine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION 2005-05-26 — — US disclosed
WO-2005028434-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS CONFORMA THERAPEUTICS CORPORATION (US) 2005-03-31 — — WO disclosed
US-6376664-B1 DETECTORS, CATALYST THE OHIO STATE UNIVERSITY 2002-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030856-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 KDM4E 1829/4885MAPT 1789/4885HSD17B10 1699/4885
US-11945811-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 KDM4E 1829/4885MAPT 1789/4885HSD17B10 1699/4885
US-20050113340-A1 2-Aminopurine analogs having HSP90-inhibiting activity HSP90AB2P, HSP90AB1, HSP90AA1 KDM4E 3577/4885MAPT 2030/4885HSD17B10 2018/4885
US-20060142214-A1 3,6-bicyclolides ABCB11, CYP2B6, CYP3A7 KDM4E 2778/4885MAPT 3856/4885HSD17B10 304/4885
US-20230406845-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 KDM4E 1291/4885MAPT 2025/4885HSD17B10 1632/4885
US-20230399301-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 KDM4E 1291/4885MAPT 2025/4885HSD17B10 1632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.